Document Detail

Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines.
MedLine Citation:
PMID:  17595773     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Prostate cancer ranks third worldwide in cancer incidence and sixth in cancer mortality among men. A number of 1,4-naphthoquinone derivatives have been found to possess significant pharmacological effects associated with marked antimicrobial and antitumor activities. In the present study the in vitro effect of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone (DCDMNQ) was evaluated on androgen-dependent (LNCaP, CWR-22) and androgen-independent (PC-3. DU-145) human prostate cancer cell lines, and/or a normal bone marrow cell line (HS-5). Moreover, the in vitro activity of this compound on cell cycle regulation and apoptosis was evaluated. MATERIALS AND METHODS: Established methods of cell viability, cell cycle, Western blot and apoptosis were used. RESULTS: The effect of DCDMNQ on LNCaP, CWR-22, PC-3, DU-145 and HS-5 cells revealed significant anti-tumor activities with IC50s, of 1, 3. 1.5, 3 and 10 microM respectively. Cell cycle analysis showed that DCDMNQ inhibited progression through the cell cycle in PC-3 and DU-145 cell lines in a time-dependent manner. The result for the CWR-22 cell line showed that DCDMNQ arrested cells in the G -phase of the cell cycle with the greatest proportion of cells in the G1-phase by day 5; however, the LNCaP cell line was inconsistent. The compound showed no effect on the cell cycle progression in the bone marrow HS-5 cell line. These findings were further validated using Western blot analysis. Furthermore, DCDMNQ induced apoptosis in the androgen-independent cells, preferentially over that of the androgen-dependent cell lines, in a time-dependent manner. CONCLUSION: Although the mechanism of action of this compound has not been completely elucidated, the effect on the cell cycle and the induction of apoptosis in different prostate cancer cell lines prompted us to carry out a more in-depth preclinical evaluation of it. This study suggests that DCDMNQ may have an impact on treatment of prostate cancer while protecting the bone marrow.
Robert L Copeland; Jharna R Das; Oladapo Bakare; Nkechi M Enwerem; Solomon Berhe; Kenguele Hillaire; Douglas White; Desta Beyene; Olakunle O Kassim; Yasmine M Kanaan
Related Documents :
9122043 - Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate ca...
15138613 - The effects of cyclooxygenase-2 inhibitors on urological cancer cells.
25242993 - Expression of pluripotency markers in human granulosa cells after embryonic stem cell e...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Anticancer research     Volume:  27     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2007 May-Jun
Date Detail:
Created Date:  2007-06-28     Completed Date:  2007-07-27     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1537-46     Citation Subset:  IM    
Department of Pharmacology, College of Medicine and Cancer Center, Howard University, Washington, DC 20059, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgens / metabolism*
Antineoplastic Agents / pharmacology*
Blotting, Western
Bone Marrow Cells / drug effects
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Flow Cytometry
Inhibitory Concentration 50
Naphthoquinones / pharmacology*
Prostatic Neoplasms / metabolism*
Retinoblastoma Protein / analysis,  metabolism
Grant Support
5-U54-CA91431/CA/NCI NIH HHS
Reg. No./Substance:
0/2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone; 0/Androgens; 0/Antineoplastic Agents; 0/Naphthoquinones; 0/Retinoblastoma Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The -463G/A polymorphism in myeloperoxidase gene and cervical cancer.
Next Document:  Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transpl...